Stockscreener 앱 받기
3.30
2.02%
-0.0682
전일 마감가:
$3.3682
열려 있는:
$3.32
하루 거래량:
3,404
Relative Volume:
0.25
시가총액:
$59.81M
수익:
-
순이익/손실:
-
주가수익비율:
-4.6531
EPS:
-0.7092
순현금흐름:
-
1주 성능:
-5.32%
1개월 성능:
+0.00%
6개월 성능:
-34.39%
1년 성능:
-21.24%
1일 변동 폭
$3.2701
$3.44
1주일 범위
$3.27
$3.56
52주 변동 폭
$2.5209
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
Compare ATHE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.30 | 61.05M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research - Defense World
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Allspring Global Investments Holdings LLC Purchases 1,956,470 Shares of Allspring Special Large Value ETF $ASLV - Defense World
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Drop in Short Interest - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
ProShares Short S&P 500 (NYSEARCA:SH) Sets New 1-Year Low – Here’s Why - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Alterity Therapeutics Ltd (ADR) trading halted, news pending - MSN
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Antalpha Platform Holding Company (NASDAQ:ANTA) Short Interest Update - Defense World
Contrasting Alterity Therapeutics (NASDAQ:ATHE) & BioHarvest Sciences (NASDAQ:BHST) - Defense World
CapEx per share of Alterity Therapeutics Ltd. Sponsored ADR – NASDAQ:ATHE - TradingView
Alterity Therapeutics stock rises after positive MSA trial data presented at conference - Investing.com
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Alterity Therapeutics (NASDAQ:ATHE) Shares Down 0.5% – What’s Next? - Defense World
Alterity Therapeutics presents ATH434-201 Phase 2 data - TipRanks
ASX recovers to shed just 0.13pc as healthcare and gold drags - Geelong Advertiser
Alterity Therapeutics raises A$20M in strategic placement - MSN
Alterity CEO to provide corporate update on ATH434 development - Investing.com
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity secures funding to advance MSA drug development - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Alterity Therapeutics LtdADR (ATHE) News, Articles, Events & Latest Updates - Stocktwits
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Ernexa Therapeutics (ERNA) Short Interest Ratio and Volume 2025 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
Trading Halts Explained - MarketBeat
IM Cannabis (IMCC) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
ATHE Financial Statements & ChartsAlterity Therapeutics LtdAdr MacroTrends - CMLviz
ATHE Pivot Points, Technical Analysis and Moving AveragesAlterity Therapeutics LtdAdr Technicals - CMLviz
Check up: A good fortnight to be a small cap health investor - Stockhead
Genprex (GNPX) Short Interest Ratio and Volume 2025 - MarketBeat
iBio (IBIO) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Integrated BioPharma (INBP) Short Interest Ratio and Volume 2025 - MarketBeat
ESSA Pharma (EPIX) Short Interest Ratio and Volume 2025 - MarketBeat
Immuron (IMRN) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Check up: Maybe next week will be better? - Stockhead
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Check up: Pot, takeovers, and COVID-19 are making investors happy - Stockhead
Maxim Group Analyst Recommendations & Stock Picks - MarketBeat
ATHE Stock Price | Alterity Therapeutics Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.34%
0.89%
자본화:
|
볼륨(24시간):